S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
Is This The End of Capitalism? (Ad)
WSC Sports Was Built on a Love for Sports. It Changed The Entire Game.
Ride These Railroad Stocks for Growth and Income
Is This The End of Capitalism? (Ad)
ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
Microsoft’s Comeback Is Now Underway
Is This The End of Capitalism? (Ad)
Can Amazon Recover Amid Tech Stock Sell-off?
KLA Corporation: Strength In A Troubled Semi-Market
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
Is This The End of Capitalism? (Ad)
WSC Sports Was Built on a Love for Sports. It Changed The Entire Game.
Ride These Railroad Stocks for Growth and Income
Is This The End of Capitalism? (Ad)
ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
Microsoft’s Comeback Is Now Underway
Is This The End of Capitalism? (Ad)
Can Amazon Recover Amid Tech Stock Sell-off?
KLA Corporation: Strength In A Troubled Semi-Market
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
Is This The End of Capitalism? (Ad)
WSC Sports Was Built on a Love for Sports. It Changed The Entire Game.
Ride These Railroad Stocks for Growth and Income
Is This The End of Capitalism? (Ad)
ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
Microsoft’s Comeback Is Now Underway
Is This The End of Capitalism? (Ad)
Can Amazon Recover Amid Tech Stock Sell-off?
KLA Corporation: Strength In A Troubled Semi-Market
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
Is This The End of Capitalism? (Ad)
WSC Sports Was Built on a Love for Sports. It Changed The Entire Game.
Ride These Railroad Stocks for Growth and Income
Is This The End of Capitalism? (Ad)
ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
Microsoft’s Comeback Is Now Underway
Is This The End of Capitalism? (Ad)
Can Amazon Recover Amid Tech Stock Sell-off?
KLA Corporation: Strength In A Troubled Semi-Market
NASDAQ:ZLAB

Zai Lab - ZLAB Stock Forecast, Price & News

$44.88
+0.41 (+0.92%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$43.70
$45.09
50-Day Range
$28.97
$48.10
52-Week Range
$20.98
$61.29
Volume
562,619 shs
Average Volume
996,863 shs
Market Capitalization
$4.39 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$97.50

Zai Lab MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
117.2% Upside
$97.50 Price Target
Short Interest
Healthy
2.78% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.41mentions of Zai Lab in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$74,160 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($5.08) to ($3.94) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

484th out of 1,055 stocks

Pharmaceutical Preparations Industry

235th out of 519 stocks


ZLAB stock logo

About Zai Lab (NASDAQ:ZLAB) Stock

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.

Receive ZLAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zai Lab and its competitors with MarketBeat's FREE daily newsletter.

ZLAB Stock News Headlines

The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Zai Lab And Novocure Announce LUNAR Study Meets Primary Endpoint
NovoCure Gaps Sharply Higher for a Breakout: How to Play It
This Good News on Cancer Sent 2 Nasdaq Stocks Soaring
What's Going On With Zai Lab Stock
Zai Lab Limited (ZLAB) Q3 2022 Earnings Call Transcript
See More Headlines
Receive ZLAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zai Lab and its competitors with MarketBeat's FREE daily newsletter.

ZLAB Company Calendar

Last Earnings
11/09/2022
Today
1/28/2023
Next Earnings (Estimated)
3/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ZLAB
Employees
1,951
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$97.50
High Stock Price Forecast
$127.00
Low Stock Price Forecast
$79.00
Forecasted Upside/Downside
+117.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-704,470,000.00
Net Margins
-301.79%
Pretax Margin
-301.41%

Debt

Sales & Book Value

Annual Sales
$144.31 million
Book Value
$14.31 per share

Miscellaneous

Free Float
91,780,000
Market Cap
$4.39 billion
Optionable
Optionable
Beta
1.18

Key Executives

  • Dr. Ying Du Ph.D. (Age 57)
    Founder, Chairperson & CEO
    Comp: $1.64M
  • Mr. Ki Chul Cho (Age 45)
    Chief Financial Officer
    Comp: $720.97k
  • Mr. Frazor Titus Edmondson III (Age 57)
    Chief Legal Officer & Corp. Sec.
    Comp: $829k
  • Dr. Harald Reinhart M.D.Dr. Harald Reinhart M.D. (Age 71)
    Pres and Head of Global Devel. for Neuroscience, Autoimmune & Infectious Diseases
    Comp: $845.94k
  • Mr. Joshua L. Smiley (Age 53)
    Chief Operating Officer
  • Dr. Peter Huang Ph.D.
    Chief Scientific Officer
  • Ms. Ann E. Beasley J.D.
    Chief Compliance Officer
  • Dr. Ning Xu M.D. (Age 58)
    Exec. VP & Head of Clinical Operations
  • Dr. Jonathan J. Wang M.B.A. (Age 41)
    MBA, Ph.D., Chief Bus. Officer
  • Dr. James Yan DABT (Age 59)
    M.D., Ph.D., Chief Operating Officer of R&D













ZLAB Stock - Frequently Asked Questions

Should I buy or sell Zai Lab stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ZLAB shares.
View ZLAB analyst ratings
or view top-rated stocks.

What is Zai Lab's stock price forecast for 2023?

3 Wall Street analysts have issued 1 year price objectives for Zai Lab's stock. Their ZLAB share price forecasts range from $79.00 to $127.00. On average, they predict the company's share price to reach $97.50 in the next twelve months. This suggests a possible upside of 117.2% from the stock's current price.
View analysts price targets for ZLAB
or view top-rated stocks among Wall Street analysts.

How have ZLAB shares performed in 2023?

Zai Lab's stock was trading at $30.70 at the beginning of the year. Since then, ZLAB stock has increased by 46.2% and is now trading at $44.88.
View the best growth stocks for 2023 here
.

When is Zai Lab's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our ZLAB earnings forecast
.

How were Zai Lab's earnings last quarter?

Zai Lab Limited (NASDAQ:ZLAB) issued its earnings results on Wednesday, November, 9th. The company reported ($1.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by $0.48. The company earned $57.54 million during the quarter, compared to analyst estimates of $53.58 million. Zai Lab had a negative trailing twelve-month return on equity of 47.41% and a negative net margin of 301.79%.

What other stocks do shareholders of Zai Lab own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zai Lab investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), Niu Technologies (NIU), JD.com (JD), Bilibili (BILI), Marvell Technology (MRVL), Baidu (BIDU), BioXcel Therapeutics (BTAI) and Baozun (BZUN).

When did Zai Lab IPO?

(ZLAB) raised $100 million in an IPO on Wednesday, September 20th 2017. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners acted as the underwriters for the IPO.

What is Zai Lab's stock symbol?

Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB."

Who are Zai Lab's major shareholders?

Zai Lab's stock is owned by a variety of institutional and retail investors. Top institutional investors include Genesis Investment Management LLP (1.52%), M&G Investment Management Ltd. (0.47%) and National Bank of Canada FI (0.04%). Insiders that own company stock include Harald Reinhart, John D Diekman, John D Diekman, Kai-Xian Chen, Peter Wirth, Tao Fu, William Ki Chul Cho, William Lis and Ying Du.
View institutional ownership trends
.

How do I buy shares of Zai Lab?

Shares of ZLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zai Lab's stock price today?

One share of ZLAB stock can currently be purchased for approximately $44.88.

How much money does Zai Lab make?

Zai Lab (NASDAQ:ZLAB) has a market capitalization of $4.39 billion and generates $144.31 million in revenue each year. The company earns $-704,470,000.00 in net income (profit) each year or ($6.22) on an earnings per share basis.

How many employees does Zai Lab have?

The company employs 1,951 workers across the globe.

How can I contact Zai Lab?

Zai Lab's mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The official website for the company is www.zailaboratory.com. The company can be reached via phone at 862161632588, via email at jsteier@burnsmc.com, or via fax at 86-21-6163-2570.

This page (NASDAQ:ZLAB) was last updated on 1/28/2023 by MarketBeat.com Staff